HDAC8 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the 143B human osteosarcoma cell line, offering a powerful loss-of-function model for HDAC8 gene studies. The CRISPR/Cas9-mediated gene disruption yields a heterogeneous pool of cells with targeted inactivation, circumventing clonal selection artifacts and enabling population-level analyses in functional genomics and drug target validation.
The 143B host cell line is a highly metastatic osteosarcoma model characterized by KRAS and TP53 mutations, which drive its aggressive proliferation, mesenchymal phenotype, and resistance to apoptosis. Originating from a bone tumor, 143B cells recapitulate critical aspects of osteosarcoma pathology, including invasiveness and deregulated cell cycle control, providing an optimal background for investigating the epigenetic regulator HDAC8 in tumor progression and metastasis.
HDAC8 functions as a class I histone deacetylase that catalyzes removal of acetyl groups from lysine residues on proteins such as the cohesin subunit SMC3, the tumor suppressor TP53, and the chromatin remodeler ARID1A. Its activity is controlled by upstream inputs including CDK1-mediated phosphorylation and cellular stress, and it interacts with corepressors NCOR1 and SMRT. Deacetylation of SMC3 is essential for proper cohesin dynamics during mitosis and gene regulation, while modulation of TP53 acetylation affects p53-mediated transcription of cell cycle inhibitor CDKN1A and apoptosis regulators like BCL2 family members, thereby integrating signals from Notch, Wnt, and p53 pathways.
In 143B cells, loss of HDAC8 disrupts deacetylation-dependent gene silencing and cohesin function, resulting in aberrant cell cycle progression, increased apoptosis, and altered expression of metastasis-associated genes. With a TP53-mutant background, this model facilitates exploration of HDAC8??s role in p53-compromised malignancies, including its impact on migratory and invasive behaviors, and serves as a platform for therapeutic target validation in osteosarcoma and related mesenchymal cancers.
These polyclonal knockout cells are compatible with diverse assays: Western blotting to confirm HDAC8 depletion and monitor acetylation of SMC3 and histones H3/H4; RT-qPCR to quantify downstream effectors such as CDKN1A and BCL2; and functional evaluations including Annexin V/PI apoptosis tests, Transwell migration/invasion studies, and flow cytometry for cell cycle profiling. Transcriptome-wide RNA-seq reveals global gene expression perturbations, while co-immunoprecipitation validates interactions with partners like MEF2A, NCOR1, and ARID1A. Moreover, drug sensitivity assays using HDAC8-selective inhibitors (e.g., PCI-34051) support translational research in neuroblastoma, colon cancer, breast cancer, T-cell lymphoma, and acute myeloid leukemia. For additional information, please contact Ascent Research.
